Protagenic Therapeutics provides update on Form 10-Q filing timeline and Nasdaq compliance

Protagenic Therapeutics plans to file its delayed Quarterly Report on Form 10-Q for the period ending June 30, 2025, due to merger-related financial statement consolidations, though a specific timeline for filing is not guaranteed.

The company received a notice from Nasdaq regarding the delayed report submission, but this notice does not impact the listing or trading of its securities, which continue to be active on the Nasdaq Capital Market.

Following the announcement, Protagenic’s stock experienced a rise of 1.41% in after-hours trading, reaching a price of $4.30.

Recommendation Rating: Moderate Interest

Protagenic Therapeutics (NASDAQ:PTIX) announced on Friday that it plans to file its Quarterly Report on Form 10-Q for the period ending June 30, 2025, soon. This filing has been delayed due to the merger-related consolidation of financial statements, which involves adjustments for purchase accounting, pro forma financial information, and necessary disclosures. While the company expects this delay to be short-lived, it cannot guarantee a specific timeline for the filing.

Additionally, Protagenic has received a notice from Nasdaq due to its inability to submit the Quarterly Report for the same period. However, this notice does not have any immediate consequences for the listing or trading of Protagenic's securities, which remain active on the Nasdaq Capital Market under the ticker symbol "PTIX." Following this announcement, the stock rose by 1.41% in after-hours trading, reaching a price of $4.30.

Source: Press Release.